Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Truist Securities Reiterates Buy Rating on Allogene (ALLO)
May 14, 2024 8:03 AM EDTTruist Securities analyst Asthika Goonewardene reiterated a Buy rating and $17.00 price target on Allogene (NASDAQ: ALLO)
The analyst comments "Two key positives from 1Q24 should make the stock more attractive, in our view: (1) Gaining EU/UK rights to lead asset... More
